Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6280 · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | ACTIVE_COMPARATOR | - |
| 4 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AZD6280 | DRUG | oral |
| Midazolam | DRUG | oral |
| Caffeine | DRUG | oral |
| Lorazepam | DRUG | 2mg tablet, oral single-dose |
| Placebo | DRUG | - |
| (11C) flumazenil | DRUG | Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280) |
Inclusion Criteria: * Healthy male subjects aged 18 to 45 years (inclusive) on Day 1. Exclusion Criteria: * Clinically relevant abnormalities in physical examinations, vital signs, clinical chemistry, hematology or urinalysis as judged by the investigator and/or sponsor. * Enrollment in another c...
AZD6280 is an investigational small molecule being developed by AstraZeneca for psychiatry, specifically studied in healthy volunteers and in anxiety. It is in Phase 1 clinical development, meaning it is still in early-stage testing and not yet approved for any use.
AZD6280 is being developed by AstraZeneca PLC, a multinational pharmaceutical company traded on the NASDAQ under the ticker symbol AZN. The drug is currently in Phase 1 clinical trials, and AstraZeneca is the sponsor of the studies listed for this compound.
AZD6280 is in Phase 1 clinical development. All four clinical trials for AZD6280 are Phase 1 studies and have been completed. The drug is investigational, meaning it has not been approved by regulatory authorities and is still undergoing early-stage testing in humans.
AZD6280 has been studied in four completed Phase 1 trials: NCT00681317, a multiple ascending dose study in healthy volunteers; NCT00681746, a PET study measuring GABAA receptor occupancy in anxiety; NCT00750802, a sedation/cognition/EEG study; and NCT00824057, a drug interaction study with midazolam and caffeine.
AZD6280 is a small molecule that targets the GABAA receptor, as indicated by a PET study using (11C) flumazenil to determine central GABAA receptor occupancy. By binding to this receptor, it may modulate inhibitory neurotransmission in the brain, which is relevant to its study in anxiety.
AZD6280 is the only name provided for this compound in the clinical trial data. There are no alternative names listed for AZD6280 in the available information, so it is not known to be the same as any other marketed or investigational drug under a different name.